MedTrace Logo

To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects

NCT06473948 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-06-25

No results posted yet for this study

Summary

Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

JMKX001899

Participants will receive JMKX001899 500mg tablet, orally once on Day 1

DRUG

JMKX001899

Participants will receive JMKX001899 750mg tablet, orally once on Day 1

DRUG

JMKX001899

Participants will receive JMKX001899 1000mg tablet, orally once on Day 1

DRUG

Placebo

Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1

Sponsors & Collaborators

  • Jemincare

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-10
Primary Completion
2024-09-24
Completion
2025-02-27

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06473948 on ClinicalTrials.gov